FDA Launches Probe of Malignancies Linked to CAR-T Therapies

FDA Launches Probe of Malignancies Linked to CAR-T Therapies

Source: 
BioSpace
snippet: 

The FDA announced Tuesday that it is investigating the “serious risk” of malignancies in patients who received treatment with BCMA- or CD19-directed autologous CAR-T cell immunotherapies.